3 results
The study will compare the overall survival (OS) between the MABp1 treated and placebo arms. Secondary endpoints will include change in lean body mass from screening to the cycle 5 assessment and change in quality of life.
The objective of this phase-3 randomized study, with a double-blind treatment period of 8 weeksduration is to evaluate the efficacy and safety of the fixed dose combinations of TAK-491 pluschlorthalidone (40/12.5 mg and 40/25 mg) in subjects with…
To analyze the molecular effects and dose-response relationship of HBOT in patients with moderate-to-severe UC refractory to medical therapy, more specifically to evaluate: - Clinical, endoscopic, histological and ultrasonographic disease activity-…